Expectations for New Pulmonary Fibrosis Drug: CEO and CFO Sell Shares Worth Hundreds of Millions

United Therapeutics Corporation’s chairman and CEO Martin Rosblatt exercised 9,500 stock options on March 24, 2026, and that same day sold 9,334 shares of common stock on the open market, realizing approximately $5.0 million (around KRW 6–7 billion) in cash while retaining a significant indirect and direct ownership stake, according to a Form 4 filing. Two days later, on March 26, CFO James Edgmond exercised 10,000 stock options and sold the same number of shares at roughly $532–540 per share, generating about $5.37 million (roughly KRW 7 billion). He continues to hold approximately $19 million worth of common stock.

On March 30, the company reported that its Tyvaso inhalation therapy for idiopathic pulmonary fibrosis (IPF) met the primary endpoint in the TETON-1 Phase 3 trial, demonstrating a 130.1 mL advantage in absolute forced vital capacity (FVC) change from baseline versus placebo at 52 weeks. United Therapeutics said it plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration to expand Tyvaso’s indication by summer 2026.

United Therapeutics is scheduled to release its first-quarter 2026 financial results before the market opens on May 6 (U.S. Eastern Time). From April 22–25, the company will present new data on pulmonary hypertension treatments, strategies to increase the supply of transplantable lungs, and xenotransplantation at the International Society for Heart and Lung Transplantation (ISHLT) annual meeting in Toronto.

Founded by Martin Rosblatt to develop a therapy for his daughter’s life-threatening pulmonary arterial hypertension, United Therapeutics is a biotech company based in Maryland and North Carolina. Its approved products include Tyvaso, Remodulin, and Orenitram for severe, rare pulmonary diseases. The company is also expanding its research into increasing the availability of transplantable lungs and advancing xenotransplantation technologies.